MedPath

Cytavis Biopharma GmbH

🇩🇪Germany
Ownership
Private
Employees
-
Market Cap
-
Website

CY-503 for the Treatment of Chemotherapy-refractory Metastatic Colorectal Cancer

Phase 2
Terminated
Conditions
Metastatic Colorectal Cancer
Interventions
Drug: Placebo
First Posted Date
2009-07-03
Last Posted Date
2013-07-10
Lead Sponsor
Cytavis Biopharma GmbH
Target Recruit Count
77
Registration Number
NCT00932724
Locations
🇦🇹

Bezirkskrankenhaus Hall, Hall in Tirol, Austria

🇦🇹

St. Vinzenz Krankenhaus Zams, Zams, Austria

🇩🇪

Onkologische Schwerpunktpraxis, Hof, Germany

and more 27 locations

CY503 for the Treatment of Malignant Melanoma Stage IV After Failure of Prior Therapy

Phase 2
Completed
Conditions
Melanoma
First Posted Date
2008-04-15
Last Posted Date
2011-06-08
Lead Sponsor
Cytavis Biopharma GmbH
Target Recruit Count
31
Registration Number
NCT00658437
Locations
🇩🇪

Haut Tumor Zentrum Charité, Berlin, Germany

🇩🇪

Dermatologisches Zentrum Elbe-Klinikum Buxtehude, Buxtehude, Germany

🇩🇪

Universitäts-Hautklinik Kiel, Kiel, Germany

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath